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We have in recent studies (1-3)  described the ability of tin-protoporphyrin to act 
as a potent competitive inhibitor of heme oxygenase, the rate limiting  enzyme of heine 
degradation, both in vitro and in vivo. This synthetic metalloporphyrin, administered 
to newborn rats, can block the major increases in heine oxygenase activity that occur 
in  various tissues  after  birth  and  can  completely prevent  the  development of the 
hyperbilirubinemia  that normally occurs postnatally. 
We report  here  that  another synthetic metalloporphyrin, chromium (Cr)  -proto- 
porphyrin, also markedly inhibits the oxidative degradation of heme to bile pigment 
and can, when administered in single doses to  neonatal animals immediately after 
birth, prevent the hyperbilirubinemia  that  characterizes the early postnatal period. 
The competitive interaction of Cr-protoporphyrin, as well as other synthetic metal° 
loporphyrins, with the human splenic heine oxygenase system is also described. The 
results of these studies indicate that  synthetic metalloporphyrins have the potential 
for  inhibiting the  rate  of heine degradation to  bile pigment in  human  as  well  as 
animal tissues. 
Materials and Methods 
Animals.  Male (140-160 g) and 15-d pregnant female Sprague Dawley rats purchased from 
Taconic Farms,  Germantown, NY  and  Holtzman, Madison,  WI,  respectively, were  used. 
Pregnancy was synchronized in the latter group of animals so that large numbers of newborn 
could be studied within the same postnatal time period; the study involved a  total of 700 
neonates divided approximately equally among the control and experimental groups described 
below. 
Chemicals.  The synthetic metalloporphyrins used in this study were purchased from Por- 
phyrin Products, Logan, UT. All other chemicals were of the highest grade obtainable from 
either Sigma Chemical Co., St Louis, MO, or Fisher Scientific Co., Pittsburgh, PA. 
Animal Treatment and Preparation of Microsomes.  Male rats were injected at subcutaneous sites 
in the nuchal region with various doses of Cr-protoporphyrin up to and including 50/~mol/kg 
body weight (bw). To prepare Cr-protoporphyrin in solution, the metalloporphyrin was taken 
up in a small volume of 0.2 M  NaOH (0.2 ml/1.0 ml of final volume of the metalloporphyrin 
solution) adjusted to pH  7.4 with  1 M  HCI, and made up to final volume with 0.9% NaCI. 
Control animals were injected with an equivalent volume of saline. The animals were allowed 
free access to water but were starved for  16 h  before killing. Microsomes were prepared as 
previously described (4). 
At birth neonates received a single subcutaneous injection of Cr-protoporphyrin (10 ktmol/ 
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kg bw) prepared as described above, but in a final volume of 0.1 ml. Control neonates received 
an equivalent volume of saline at birth. The neonates remained with their mothers throughout 
the experiment; groups of neonates (6-30 animals per group) were killed at the times indicated 
in the figures; assays were performed for serum bilirubin and  heme oxygenase as described 
below. 
Preparation of Microsomesfrom Human Spleen.  Samples of human spleen, obtained during the 
course of operative procedures requiring spleen removal, were provided to us through the Tissue 
Procurement Service at the Memorial Sloan-Kettering Cancer Center, New York. The tissue 
was washed thoroughly with 0.9% saline to remove excess blood and then minced, homogenized 
in  3  vol of 0.1  M  potassium phosphate buffer pH  7.4,  containing 0.25  M  sucrose, and  the 
microsomal fraction was prepared as described previously (4). 
Enzyme Assays.  Heme oxygenase was assayed as described (1), and bilirubin formation was 
calculated on  the basis of an  extinction coefficient of 40  mM -1  cm  -1 and  the difference in 
absorbance between 464 nm and 530 nm. Heine oxygenase activity was expressed as nanomoles 
bilirubin formed  per  milligrams microsomal  protein  per  h.  All assays were  performed  in 
duplicate on an Aminco Chance DW2A spectrophotometer in the split-beam mode. 
Total bilirubin was estimated fluorometrically  by the method of Roth  (5);  the variation in 
replicate serum samples was <5%.  Cr-protoporphyrin did not interfere with bilirubin deter- 
ruination in this assay. Protein concentration was determined using crystalline serum bovine 
albumin as standard by the method of Lowry et al. (6). The data were analyzed by the standard 
t test and the value P <  0.05 was regarded as significant. 
Results 
The Dose-dependent Effect of Cr-Protoporphyrin on Heine  Oxygenase Activity in Liver.  Cr- 
protoporphyrin  administered  in  doses  ranging  from  0.5  to  50  #mol/kg  bw  was 
examined in adult male rats for its effects in vivo on heme oxygenase, the rate limiting 
enzyme  (7,  8)  of heine  degradation  (Table  I).  Hepatic  heine  oxygenase  activity, 
measured  16  h  after  Cr-protoporphyrin  administration,  was  lowered  in  a  dose- 
dependent  manner.  Even  at  the  lowest  dose  of the  metalloporphyrin studied  (0.5 
#mol/kg bw), heine oxygenase activity was diminished by >50%.  Splenic and renal 
heine oxygenase activities were also lowered in a  dose-dependent manner;  however, 
at the lowest dose of Cr-protoporphyrin examined  (0.5 #mol/kg bw), no significant 
decrease in  enzyme  activity was  detected in  either organ  (results not  shown).  This 
effect of Cr-protoporphyrin on enzyme activity was long lasting. A  single administra- 
tion of the metalloporphyrin at a  dose of 1/~mol/kg bw resulted in a  rapid (within 5 
h) lowering of hepatic heme oxygenase activity to a  level, by 8  h, <50% of the initial 
control level (1.16  +  0.13  and  2.56  +  0.22,  respectively) where  it  remained for the 
succeeding 14 d. 
Competitive  Inhibition  of Heine  Oxygenase Activity  In  Vitro by  Cr-Protoporphyrin.  The 
apparent Km for  heine  in  the  rat  spleen  microsomal  heme  oxygenase system  was 
determined to be 7.68 #M, which is within the range reported previously (9,  10). The 
addition of Cr-protoporphyrin (0.025  #M)  to splenic heme oxygenase resulted in  a 
marked  competitive  inhibition  of enzyme  activity,  with  a  greater  than  threefold 
increase (7.68-25.64 #M  [Fig.  1])  in  the apparent  Km for heme.  The Ki  (inhibition 
constant)  for  Cr-protoporphyrin  was  determined  to  be  0.011  /.tM.  This  value  is 
identical to the Ki value reported previously for tin (Sn-) protoporphyrin (1). 
On the basis of these findings (Table I, Fig. 1) Cr-protoporphyrin was administered 
to neonatal rats at birth to determine if this metalloporphyrin was capable of blocking 
the  development  of hyperbilirubinemia in  the  postnatal  period.  The  dose  of Cr- 
protoporphyrin chosen  (10 #mol/kg bw), to be administered in a  single dose at birth 
to neonatal  rats,  was  sufficient to  block splenic as well as hepatic  and  renal  heme 
oxygenase activity in adult animals. 1880  DRUMMOND  AND  KAPPAS  BRIEF  DEFINITIVE  REPORT 
TABLE  I 
Effect of Cr-Protoporphyrin on Heme Oxygenase Activity in Rat Liver 
Dose  Heine oxygenase 
ltmol/kg  b.w.  nmol bilirubin/mg ph 
Control  2.27 ±  0.18 
0.5  1.06" ±  0.06 
1  0.89* ±  0.26 
5  0.51" +_ 0.11 
50  0.29* +  0.04 
Adult male rats  (three to six animals) were administered Cr-protoporphyrin subcutane- 
ously  at  the doses indicated.  Animals were starved for  16 h  before killing.  Mierosomal 
fractions  were  prepared  and  heme  oxygenase  assayed  as  described  in  Materials  and 
Methods. 
* P <  0.05 compared with control. 
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Ftc.  1,  Double  reciprocal  plot  of substrate  concentration  vs.  velocity  of  rat  spleen  rnicrosomal 
heme oxygenase  (0)  and in the presence of Cr-protoporphyrin  (0.025/tM)  (O). 
Effects of Cr-Protoporphyrin  on Heine  Oxygenase  Activity and Serum  Bilirubin  Levels in the 
Neonate.  The effect of a single dose (10 ~mol/kg) of Cr-protoporphyrin administered 
at  birth  on  hepatic  and  spleen  heme oxygenase  activities  is  shown  in  Fig.  2.  This 
enzyme activity rose rapidly in liver after birth, as expected, reaching a level fourfold 
above  normal adult  levels  at  5  d  before  commencing  to decline  to  adult  levels.  In 
neonates receiving Cr-protoporphyrin,  this liver enzyme activity declined  promptly, 
where it remained at levels well below normal adult levels throughout the 14-d period 
of study.  This dose of Cr-protoporphyrin also immediately and profoundly lowered 
(~80%)  renal heine oxygenase activity, to a  point where it remained throughout the 
entire  period  of  study  (results  not  shown).  Splenic  heme  oxygenase  activity  in 
untreated neonates followed the normal course of postnatal development, being low 
at birth and increasing rapidly in the postnatal period to reach normal adult levels by 
day 14 (Fig. 2). Administration of Cr-protoporphyrin (10 ~mol/kg bw) prevented this 
increase;  indeed the splenic heine oxygenase activity declined markedly until day 5, 
when it began to increase towards the levels characteristic of the normal adult animal. 
The total bilirubin concentration in the serum of untreated neonates increased after 
birth, as expected, to a maximum at day 2, before commencing to decline towards the 
range typical  of the  normal adult  animal  (Fig.  3).  Administration of Cr-protopor- 
phyrin (10/xmol/kg bw) at birth prevented the increase in serum bilirubin at day 2; 
thereafter serum bilirubin  levels remained lower than those in the control group for DRUMMOND  AND  KAPPAS  BRIEF  DEFINITIVE  REPORT  1881 
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Fie.  2.  The activity of heme oxygenase in liver and spleen of the neonate after a  single injection 
of Cr-protoporphyrin (10 #mol/kg b.w.) immediately after birth. Hepatic heme oxygenase in control 
(O), and Cr-protoporphyrin (O) -treated neonates and splenic heine oxygenase in control (O), and 
Cr-protoporphyrin  (A)  -treated neonates was assayed in duplicate as described in Materials and 
Methods. Each point represents the average of three litters (10-12 animals/litter). The values for 
hepatic heine oxygenase at  day 5  were  10.13 +  0.82 and  1.22  +  0.25 nmol bilirubin formed/rag 
microsomal protein per h  in control and Cr-protoporphyrin-treated neonates, respectively. 
0.5 
Time  (d) 
Fla.  3.  The levels of serum bilirubin in control (Q) and Cr-protoporphyrin-treated  (O)  neonates. 
Each  time  point  represents the  average  of pooled  serum samples. The  mean  values for  serum 
bilirubin from day 2 through day 14 were significantly lower for Cr-protoporphyrin-treated neonates 
than for the respective controls (P <  0.05 at each time point). 
the initial  14 d after birth. The same dose of Sn-protoporphyrin was shown earlier (3) 
to prevent the prompt postnatal rise of serum bilirubin levels in the newborn rat. At 
the dose studied (10/xmol/kg bw), Cr-protoporphyrin produced no detrimental effects 
in the newborn animals. 
Competitive Inhibition of Heme Oxidation in Human Spleen Microsomes by Synthetic Metallo- 
porphyrins.  The  apparent  Km  for  heine  in  the  human  spleen  microsomal  heme 
oxygenase system was determined to be  19.04 ±  0.08 #M, which is within the range 
reported previously for this tissue (11). Using both Dixon and Lineweaver-Burk plots, 
the Ki for each of five synthetic metalloporphyrins in this system was determined; the 
values for Cr- and Sn-protoporphyrins indicate that  these compounds were signifi- 
cantly more potent as competitive inhibitors of heme oxidation in human spleen than 
manganese, cobalt, or zinc protoporphyrins (Table II). 
Discussion 
This  study  demonstrates  that  Cr-protoporphyrin,  when  administered  to  rats  in 
single, small doses immediately after birth, can markedly inhibit the major increases 1882  DRUMMOND  AND  KAPPAS  BRIEF  DEFINITIVE  REPORT 
TABLE  II 
Ki of a Series of Metalloporphyrins  for Human Spleen Microsomal Heme 
Oxygenase 
Metalloporphyrin  Ki 
#M 
Sn-protoporphyrin  0.018 ±  0.001 
Cr-protoporphyrin  0.033 ±  0.009 
Mn-protoporphyrin  0.530 +_. 0.140 
Co-protoporphyrin  0.670 ±  0.190 
Zn-protoporphyrin  2.523 _+ 0.720 
Ki were determined using double reciprocal plots of substrate concentration vs. velocity of 
heine oxygenase in the presence of the appropriate metalloporphyrin and by Dixon plots. 
No significant  difference  was found between Ki determined by the two methods. 
that develop in the heme oxygenase activities of various tissues and can also prevent 
the  hyperbilirubinemia  that  normally  occurs  postnatally.  Cr-protoporphyrin  is  a 
powerful competitive inhibitor of heine oxygenase activity in vitro (Fig. 3, Table II). 
The Ki (0.011/.tM)  of Cr-protoporphyrin for rat spleen microsomal heine oxygenase 
is identical to that previously reported for Sn-protoporphyrin (1).  The rapidity with 
which heine oxygenase activity is lowered in vivo after Cr-protoporphyrin adminis- 
tration is undoubtedly attributable to the marked ability of this metalloporphyrin to 
competitively inhibit  heine  degradation;  this  effect cannot  be due  to  inhibition  of 
enzyme synthesis as the half-life of heine oxygenase has been previously reported to 
be ~16 h  (12,  13). 
Cr-protoporphyrin  inhibition  of heine  oxygenase  in  the  rat  spleen  microsomal 
system is competitive in nature  (Fig.  1), with an affinity of the metalloporphyrin for 
the  enzyme  identical  to  that  previously  determined  for  Sn-protoporphyrin.  Both 
compounds also competitively inhibit the rate of heine oxidation in the human spleen 
microsomal heine oxygenase system to a comparable degree (Table II). The marked 
affinities of these metalloporphyrins for human spleen heine oxygenase, as reflected in 
the Ki values  (Table II), greatly exceeded those of several other metalloporphyrins 
examined and was consistent with their ability to not only inhibit  heine oxygenase 
activities  in  various  animal  tissues  in  vivo  and  in  vitro,  but  also  to  concurrently 
suppress the hyperbilirubinemia which  normally occurs in the immediate postnatal 
period  (1,  2).  As we noted earlier (1), the ability of a  synthetic metalloporphyrin to 
inhibit  heme  oxygenase  (1-3,  10,  14,  15)  does  not  of  itself  guarantee  that  the 
compound  in  question  will  have  the  requisite  biological characteristics  in  vivo  to 
suppress hyperbilirubinemia. Whole animal studies are essential to establish this point 
because  of  the  physiological  and  pharmacokinetic  variables  involved  in  such  a 
response. The  ineffectiveness of Mn-  or  Zn-protoporphyrin in  preventing neonatal 
hyperbilirubinemia  (1,  3)  and  the  dual  properties  (16)  of  Co-protoporphyrin  of 
inhibiting heme oxygenase in vitro while potently inducing the enzyme in vivo affirm 
this view. 
The possibility of suppressing neonatal jaundice  by appropriately regulating  the 
rate of heine oxidation in vivo was proposed in a previous study from this laboratory 
(17). Our recent studies with Sn-protoporphyrin (1, 2) have shown that this compound 
can effectively exert such a  regulatory action in the rat neonate. Cr-protoporphyrin, 
as the data in the present report indicate, exerts a similar regulatory action. 
Summary 
The synthetic metalloporphyrin, Cr-protoporphyrin, is a potent competitive inhib- DRUMMOND  AND KAPPAS  BRIEF  DEFINITIVE  REPORT  1883 
itor of heme oxygenase activity in rat spleen, liver, and kidney. When administered 
to  neonatal animals in  a  single  dose  immediately after  birth,  Cr-protoporphyrin 
suppresses postnatal hyperbilirubinemia  and produces a  marked and sustained low- 
ering of heme oxidation activity in liver, spleen, and kidney. The metalloporphyrin 
also potently inhibited the rate of heine degradation to bile pigment in human spleen. 
The  authors wish  to  thank  Ms.  Susan  Spinner and  Ms.  Beth  Sheard  for  their  technical 
assistance and Mrs. Heidemarie Robinson for the preparation of this manuscript. 
Received  for publication  15 September 1982. 
References 
1.  Drummond, G. S., and A. Kappas. 1981. Prevention  of neonatal hyperbilirubinemia  by tin 
protoporphyrin IX, a potent competitive inhibitor of heme oxidation. Proc. Natl. Acad.  Sci. 
U. S. A. 78:6466. 
2.  Kappas, A., and G. S. Drummond. 1982. The regulation of heme oxidation by synthetic 
met  alloporphyrins:  experimental  and clinical  implications.  In Microsomes, Drug Oxidations 
and Drug Toxicity. R. Sato, and R. Kato, editors. Japan Scientific Societies Press, Tokyo, 
Wiley-Interscience,  New York. 629-636. 
3.  Drummond, G. S., and A. Kappas. 1982. Chemoprevention  of neonatal  jaundice: potency 
of tin protoporphyrin in an animal model. Science (Wash. D. C.). 217:1250. 
4.  Drummond, G.  S.,  and  A.  Kappas.  1979. Manganese and  zinc  blockade of enzyme 
induction: studies with microsomal heme oxygenase. Proc. Natl. Acad.  ScL  U. S. A. 76:5331. 
5.  Roth, M.  1967. Dosage fluorimetrique de la bilirubine.  Clin.  Chim.  Acta.  17:487. 
6.  Lowry, O., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement 
with the Folin phenol reagent.J. Biol.  Chem. 193:265. 
7.  Tenhunen, R., H. S. Marver, and R. Schmid. 1968. The enzymatic conversion of heme to 
bilirubin  by microsomal heme oxygenase. Proc. Natl. Acad. Sci.  U. S. A. 61:748. 
8.  Tenhunen, R.,  H.  S.  Marver,  and  R.  Schmid.  °1969. Microsomal  heme  oxygenase-- 
characterization of the enzyme.J. Biol.  Chem. 244:6388. 
9.  Tenhunen, R.  1976. The enzymatic conversion of heine to bilirubin  in vivo. Ann.  Clin.  Res. 
8(Suppl.) 17:2. 
10.  Maines, M. D., and A. Kappas. 1977. Enzymatic oxidation of cobalt protoporphyrin. IX. 
Observations on the mechanism of heme oxygenase action. Biochemistry.  16:419. 
11.  Schacter, B.  A.,  B.  Yoda, and L.  G.  Israels.  1976. Human spleen oxygenase in normal, 
hemolytic and other pathological states.  Ann.  Clin.  Res. 8(Suppl.)17:28. 
12.  Drummond, G. S., and A.  Kappas.  1980. Metal ion interactions in the control of haem 
oxygenase induction in liver and kidney. Biochem. J.  192:637. 
13.  Sardana, M. K., S. Sassa,  and A. Kappas.  1982. Metal ion-mediated regulation of heme 
oxygenase induction in cultured avian liver cells.J. Biol.  Chem. 257:4806. 
14.  Yoshinaga, T., S. Sassa, and A. Kappas. 1982. Purification and properties of bovine spleen 
heme oxygenase: amino acid composition  and sites of action of inhibitors  of heme oxidation. 
J.  Biol.  Chem. 257:7778. 
15.  Maines, M. D. 1981. Zinc-protoporphyrin  is a selective inhibitor  of heme oxygenase activity 
in the neonatal rat. Biochim.  Biophys.  Acta 673:339. 
16.  Drummond, G. S., and A. Kappas.  1982. The dual ability of Co-heme (cobalt protopor- 
phyrin  IX)  to  alter  heme  oxygenase activity;  potent  induction in  vivo and  profound 
competitive inhibition in  vitro.  In  Microsomes, Drug Oxidations, and Drug Toxicity, R. 
Sato and R. Kato, editors. Japan Scientific Societies Press, Tokyo, Wiley/Interscience,  New 
York. 423. 
17.  Maines,  M.  D.,  and  A.  Kappas.  1975. Study  of  the  developmental pattern  of heme 
catabolism in liver and the effects  of cobalt on cytochrome P-450 and the rate of heme 
oxidation during the neonatal period.J. Exp.  Med.  141:1400. 